A recent study investigated COVID-19 outcomes in patients with primary and secondary immunodeficiency, comparing hospitalization rates and mortality between both vaccinated and unvaccinated patients.
Read More »Authors of a recent study looked into the effects of NSAIDs and corticosteroids on inflammation from SARS-CoV-2 infection, as well as their ability to reduce disease progression, including hospitalization.
Read More »Topline results of a recent clinical trial showed that infliximab or abatacept “substantially improve[ed] clinical status and reduc[ed] deaths” in adult patients hospitalized with severe COVID-19. These drugs are often used to treat certain autoimmune diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ankylosing spondylitis.
Read More »The FDA has revised its emergency use authorization for AstraZeneca’s Evusheld, a monoclonal antibody treatment for COVID-19. Due to emerging data, it has been observed that the original 150mg dose of each monoclonal antibody may be less likely to prevent infection than originally indicated. Thus, the FDA has authorized a double dose of each antibody for immunocompromised patients.
Read More »